ArticleNeuro-oncology practice2017

Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.

Elizabeth J Hovey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.